{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:01:05Z","timestamp":1792022465126,"version":"4.4.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1001\/jamaoncol.2018.3542","type":"journal-article","created":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T18:35:43Z","timestamp":1535999743000},"page":"1535","source":"Crossref","is-referenced-by-count":133,"title":["Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer"],"prefix":"10.1001","volume":"4","author":[{"given":"Charles C.","family":"Peyton","sequence":"first","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Tang","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard R.","family":"Reich","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounsif","family":"Azizi","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Chipollini","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio M.","family":"Pow-Sang","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Manley","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Poch","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade J.","family":"Sexton","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayer","family":"Fishman","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingsong","family":"Zhang","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"9","key":"coi180066r1","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"2","key":"coi180066r2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","article-title":"Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.","volume":"48","author":"Advanced Bladder Cancer (ABC) Meta-analysis Collaboration","year":"2005","journal-title":"Eur Urol"},{"issue":"16","key":"coi180066r3","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.","volume":"29","author":"Griffiths","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi180066r4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2016.06.020","article-title":"Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer.","volume":"71","author":"Alfred Witjes","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"coi180066r5","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of non-metastatic muscle-invasive bladder cancer: AUA\/ASCO\/ASTRO\/SUO guideline.","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"issue":"10","key":"coi180066r6","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.6004\/jnccn.2017.0156","article-title":"Bladder cancer, version 5.2017, NCCN Clinical Practice Guidelines in Oncology.","volume":"15","author":"Spiess","year":"2017","journal-title":"J Natl Compr Canc Netw"},{"issue":"16","key":"coi180066r7","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1200\/JCO.2010.34.0471","article-title":"Kuhn\u2019s paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift?","volume":"29","author":"Bajorin","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"coi180066r8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.6004\/jnccn.2009.0003","article-title":"Integrating perioperative chemotherapy into the treatment of muscle-invasive bladder cancer: strategy versus reality.","volume":"7","author":"Donat","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"coi180066r9","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.urolonc.2009.03.021","article-title":"Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer.","volume":"29","author":"Porter","year":"2011","journal-title":"Urol Oncol"},{"key":"coi180066r10","first-page":"142","article-title":"Neoadjuvant M-VAC of invasive bladder cancer: G.U.O.N.E. multicenter phase III trial","volume":"33","author":"Bassi","year":"1998","journal-title":"Eur Urol"},{"key":"coi180066r11","first-page":"345","article-title":"Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial.","volume":"8","author":"GISTV (Italian Bladder Cancer Study Group)","year":"1996","journal-title":"J Chemother"},{"issue":"9178","key":"coi180066r12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(99)02292-8","article-title":"Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists.","volume":"354","author":"International collaboration of trialists","year":"1999","journal-title":"Lancet"},{"issue":"12","key":"coi180066r13","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse.","volume":"64","author":"Sternberg","year":"1989","journal-title":"Cancer"},{"issue":"7","key":"coi180066r14","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"issue":"21","key":"coi180066r15","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi180066r16","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1200\/JCO.2001.19.10.2638","article-title":"Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924.","volume":"19","author":"Sternberg","year":"2001","journal-title":"J Clin Oncol"},{"issue":"18","key":"coi180066r17","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2013.52.4785","article-title":"Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates.","volume":"32","author":"Choueiri","year":"2014","journal-title":"J Clin Oncol"},{"issue":"18","key":"coi180066r18","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1200\/JCO.2013.53.2465","article-title":"Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.","volume":"32","author":"Plimack","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15","key":"coi180066r19","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/cncr.v121.15","article-title":"Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.","volume":"121","author":"Galsky","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"coi180066r20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","article-title":"Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.","volume":"67","author":"Zargar","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"coi180066r21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"18","key":"coi180066r23","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1002\/cncr.v115:18","article-title":"Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.","volume":"115","author":"Sonpavde","year":"2009","journal-title":"Cancer"},{"issue":"6","key":"coi180066r24","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1093\/annonc\/mdu126","article-title":"Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study JCOG0209.","volume":"25","author":"Kitamura","year":"2014","journal-title":"Ann Oncol"},{"issue":"17","key":"coi180066r25","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"9","key":"coi180066r26","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1002\/cncr.v113:9","article-title":"A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.","volume":"113","author":"Dash","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"coi180066r27","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/j.urolonc.2012.07.005","article-title":"Neoadjuvant chemotherapy with gemcitabine\/cisplatin vs. methotrexate\/vinblastine\/doxorubicin\/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.","volume":"31","author":"Fairey","year":"2013","journal-title":"Urol Oncol"},{"issue":"2","key":"coi180066r28","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.urology.2011.10.050","article-title":"Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.","volume":"79","author":"Yeshchina","year":"2012","journal-title":"Urology"},{"issue":"2","key":"coi180066r29","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis.","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"issue":"6","key":"coi180066r30","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer.","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"issue":"1","key":"coi180066r31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cncr.26240","article-title":"Efficient delivery of radical cystectomy after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a multidisciplinary approach.","volume":"118","author":"Alva","year":"2012","journal-title":"Cancer"},{"issue":"6","key":"coi180066r32","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1016\/j.juro.2017.12.062","article-title":"Neoadjuvant dose dense MVAC versus GC in patients with cT3-4aN0M0 bladder cancer treated with radical cystectomy.","volume":"199","author":"Zargar","year":"2018","journal-title":"J Urol"},{"issue":"11","key":"coi180066r34","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s00345-017-2065-x","article-title":"Dose dense MVAC prior to radical cystectomy: a real-world experience.","volume":"35","author":"Zargar","year":"2017","journal-title":"World J Urol"},{"issue":"3","key":"coi180066r35","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"19","key":"coi180066r36","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.","volume":"17","author":"D\u2019Agostino","year":"1998","journal-title":"Stat Med"},{"issue":"7","key":"coi180066r37","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments.","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"coi180066r22","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE): Version 4.0","author":"National Cancer Institute","year":"2010"},{"key":"coi180066r33","unstructured":"Southwest Oncology Group NCI. A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02177695. Accessed December 12, 2017."}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2698043","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T11:01:25Z","timestamp":1541674885000},"score":1,"resource":{"primary":{"URL":"http:\/\/oncology.jamanetwork.com\/article.aspx?doi=10.1001\/jamaoncol.2018.3542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2018.3542","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}